WELCOME TO OUR
2023 HD REACH EDUCATIONAL SERIES
uniQure is delivering on the promise of gene therapy – single treatments with potentially transformative results. We are utilizing our technology to advance a pipeline of gene therapies to treat patients with neurodegenerative diseases, and other severe genetic diseases. We are currently conducting a phase 1/2 trial in Huntington’s disease, the first gene therapy ever in a clinical trial for HD. Our gene therapy for hemophilia B was approved by the US FDA in 2022.
Our clinic provides care to those who are living with Huntington's disease or who are at risk for the disease. We are North Carolina's only nationally designated Huntington's Disease Society of America (HDSA) Center of Excellence, which recognizes expertise in diagnosing and managing Huntington's disease. Our comprehensive team includes movement disorders specialists; physical, occupational, and speech therapists; clinical social workers; a clinical pharmacist; nurses, and others who work together to provide comprehensive care to patients and families at any stage of Huntington's disease.